Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS).

Published in: British journal of clinical pharmacology (2022)

This study detected a previously unreported signal of disproportionate CVA reporting with the real-world use of risankizumab. Further long-term observational data will be necessary to better characterize this unconfirmed potential safety signal.

Keyphrases

adverse drug
electronic health record
human health
big data
cross sectional
risk assessment
machine learning